What should be considered on design of a colon-specific prodrug?

Bibliography

• Braun K, Pipkorn R, Waldeck W. Development and characterization of drug delivery systems for targeting mammalian cells and tissues: a review. Curr Med Chem 2005;12:1841-58
   PubMed Web of Science ®Google Scholar
• Langer R. Drug delivery and targeting. Nature 1998;392:5-10
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov Today 2002;7:1138-43
   PubMed Web of Science ®Google Scholar
• Ast G. Drug-targeting strategies for prostate cancer. Curr Pharm Des 2003;9:455-66
   PubMed Web of Science ®Google Scholar
• Haas M, Moolenaar F, Meijer DK, Specific drug delivery to the kidney. Cardiovasc Drugs Ther 2002;16:489-96
   PubMed Web of Science ®Google Scholar
• de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007;47:323-55
   PubMed Web of Science ®Google Scholar
• Takahashi-Nishioka T, Yokogawa K, Tomatsu S, Targeted drug delivery to bone: pharmacokinetic and pharmacological properties of acidic oligopeptide-tagged drugs. Curr Drug Discov Technol 2008;5:39-48
   PubMedGoogle Scholar
• Wilding I. Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 2000;17:557-620
   PubMed Web of Science ®Google Scholar
• Pavan B, Dalpiaz A, Ciliberti N, Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 2008;13:1035-65
   PubMed Web of Science ®Google Scholar
• Shareef MA, Khar RK, Ahuja A, Colonic drug delivery: an updated review. AAPS PharmSci 2003;5:E17
   PubMedGoogle Scholar
• Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 2008;15:1802-26
   PubMed Web of Science ®Google Scholar
• Jain SK, Jain A. Target-specific drug release to the colon. Expert Opin Drug Deliv 2008;5:483-98
   PubMed Web of Science ®Google Scholar
• Patel M, Shah T, Amin A. Therapeutic opportunities in colon-specific drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2007;24:147-202
   PubMed Web of Science ®Google Scholar
• Friend DR. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:591-603
   PubMed Web of Science ®Google Scholar
• Sinha V, Singh A, Kumar RV, Oral colon-specific drug delivery of protein and peptide drugs. Crit Rev Ther Drug Carrier Syst 2007;24:63-92
   PubMed Web of Science ®Google Scholar
• Saffran M, Kumar GS, Savariar C, A new approach to the oral administration of insulin and other peptide drugs. Science 1986;233:1081-4
   PubMed Web of Science ®Google Scholar
• Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2001;18:433-58
   PubMed Web of Science ®Google Scholar
• Kinget R, Kalala W, Vervoort L, Colonic drug targeting. J Drug Target 1998;6:129-49
   PubMed Web of Science ®Google Scholar
• Van den Mooter G. Colon drug delivery. Expert Opin Drug Deliv 2006;3:111-25
   PubMedGoogle Scholar
• Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005;57:247-65
   PubMed Web of Science ®Google Scholar
• Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003;6:33-66
   PubMed Web of Science ®Google Scholar
• Sinha VR, Kumria R. Colonic drug delivery: prodrug approach. Pharm Res 2001;18:557-64
   PubMed Web of Science ®Google Scholar
• Chae SY, Jang MK, Nah JW. Influence of molecular weight on oral absorption of water soluble chitosans. J Control Release 2005;102:383-94
   PubMed Web of Science ®Google Scholar
• Ungell AL, Nylander S, Bergstrand S, Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998;87:360-6
   PubMed Web of Science ®Google Scholar
• Doh MJ, Jung YJ, Kim I, Synthesis and in vitro properties of prednisolone 21-sulfate sodium as a colon-specific prodrug of prednisolone. Arch Pharm Res 2003;26:258-63
   PubMed Web of Science ®Google Scholar
• Jung YJ, Lee JS, Kim YM. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J Pharm Sci 2000;89:594-602
   PubMed Web of Science ®Google Scholar
• Friend DR, Chang GW. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem 1984;27:261-6
   PubMed Web of Science ®Google Scholar
• Minami K, Hirayama F, Uekama K. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J Pharm Sci 1998;87:715-20
   PubMed Web of Science ®Google Scholar
• Harboe E, Larsen C, Johansen M, Macromolecular prodrugs. XV. Colon-targeted delivery–bioavailability of naproxen from orally administered dextran-naproxen ester prodrugs varying in molecular size in the pig. Pharm Res 1989;6:919-23
   PubMed Web of Science ®Google Scholar
• Leopold CS, Friend DR. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. J Pharmacokinet Biopharm 1995;23:397-406
   PubMedGoogle Scholar
• Brown JP, McGarraugh GV, Parkinson TM, A polymeric drug for treatment of inflammatory bowel disease. J Med Chem 1983;26:1300-7
   PubMed Web of Science ®Google Scholar
• Sakuma S, Lu ZR, Kopeckova P, Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J Control Release 2001;75:365-79
   PubMed Web of Science ®Google Scholar
• Wiwattanapatapee R, Lomlim L, Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release 2003;88:1-9
   PubMed Web of Science ®Google Scholar
• Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 1973;25:451-523
   PubMed Web of Science ®Google Scholar
• Haeberlin B. FDR. Anatomy and physiology of the gastrointestinal tract: Implication for colonic drug delivery. In: Friend DR, editor, Oral colon-specific drug delivery. CRC Press, Inc., Boca Raton, FL; 1992. p. 1-43
   Google Scholar
• Brown JP. Reduction of polymeric azo and nitro dyes by intestinal bacteria. Appl Environ Microbiol 1981;41:1283-6
   PubMed Web of Science ®Google Scholar
• Faigle JW. Drug metabolism in the colon wall and lumen. In: Bieck PR, editor, Colonic drug absorption and metabolism. Marcel Dekker, Inc.; 1993. p. 29-54
   Google Scholar
• Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003;18:3-18
   PubMed Web of Science ®Google Scholar
• Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-9
   PubMed Web of Science ®Google Scholar
• Keighley MR, Arabi Y, Dimock F, Influence of inflammatory bowel disease on intestinal microflora. Gut 1978;19:1099-104
   PubMed Web of Science ®Google Scholar
• Carrette O, Favier C, Mizon C, Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 1995;40:2641-6
   PubMed Web of Science ®Google Scholar
• Bhat P, Shantakumari S, Rajan D, Bacterial flora of the gastrointestinal tract in southern Indian control subjects and patients with tropical sprue. Gastroenterology 1972;62:11-21
   PubMed Web of Science ®Google Scholar
• Egan LJ, Sandborn WJ. Drug therapy of inflammatory bowel disease. Drugs Today (Barc) 1998;34:431-46
   PubMed Web of Science ®Google Scholar
• Kim D, Hong S, Jung S, Synthesis and Evaluation of N-Nicotinoyl-2- {2-(2-Methyl-5-Nitroimidazol-1-yl)Ethyloxy}-D,L-Glycine as a Colon-Specific Prodrug of Metronidazole. J Pharm Sci 2009;98(11):4161-9
   PubMed Web of Science ®Google Scholar
• Lee JS, Jung YJ, Doh MJ, Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev Ind Pharm 2001;27:331-6
   PubMed Web of Science ®Google Scholar
• Pradhan A, Majumdar MK. Metabolism of some drugs by intestinal lactobacilli and their toxicological considerations. Acta Pharmacol Toxicol (Copenh) 1986;58:11-5
   PubMedGoogle Scholar
• Nolen HW III, Friend DR. Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome. Pharm Res 1994;11:1707-11
   PubMed Web of Science ®Google Scholar
• Simpkins JW, Smulkowski M, Dixon R, Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther 1988;244:195-205
   PubMed Web of Science ®Google Scholar
• Rodrigues CM, Kren BT, Steer CJ, The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995;109:1835-44
   PubMed Web of Science ®Google Scholar
• Lee JS, Jung YJ, Kim YM. Synthesis and evaluation of N-acyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil. J Pharm Sci 2001;90:1787-94
   PubMed Web of Science ®Google Scholar
• Kim H, Kong H, Choi B, Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res 2005;22:1499-509
   PubMed Web of Science ®Google Scholar
• Kobashi K, Nishimura T, Kusaka M, Metabolism of sennosides by human intestinal bacteria. Planta Med 1980;40:225-36
   PubMed Web of Science ®Google Scholar
• Krishnaiah YS, Veer Raju P, Dinesh Kumar B, Development of colon targeted drug delivery systems for mebendazole. J Control Release 2001;77:87-95
   PubMed Web of Science ®Google Scholar
• Krishnaiah YS, Satyanarayana V, Kumar BD, Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J Drug Target 2002;10:247-54
   PubMed Web of Science ®Google Scholar
• Sinha VR, Bhinge JR, Kumria R, Development of pulsatile systems for targeted drug delivery of celecoxib for prophylaxis of colorectal cancer. Drug Deliv 2006;13:221-5
   PubMed Web of Science ®Google Scholar
• Tozaki H, Nishioka J, Komoike J, Enhanced absorption of insulin and (Asu(1,7))eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. J Pharm Sci 2001;90:89-97
   PubMed Web of Science ®Google Scholar
• Tozaki H, Komoike J, Tada C, Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997;86:1016-21
   PubMed Web of Science ®Google Scholar
• Van den Mooter G, Maris B, Samyn C, Use of azo polymers for colon-specific drug delivery. J Pharm Sci 1997;86:1321-7
   PubMed Web of Science ®Google Scholar
• Larsen C, Jensen BH, Olesen HP. Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. Acta Pharm Nord 1991;3:71-6
   PubMedGoogle Scholar
• Robinson MG. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease. Gastroenterol Clin North Am 1989;18:43-50
   PubMed Web of Science ®Google Scholar
• Chan RP, Pope DJ, Gilbert AP, Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 1983;28:609-15
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sasaki K, Kurosaki Y, Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid. J Drug Target 1994;2:123-31
   PubMed Web of Science ®Google Scholar
• Dhaneshwar SS, Gairola N, Kandpal M, Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease. Bioorg Med Chem Lett 2007;17:1897-902
   PubMed Web of Science ®Google Scholar
• Lu ZR, Shiah JG, Sakuma S, Design of novel bioconjugates for targeted drug delivery. J Control Release 2002;78:165-73
   PubMed Web of Science ®Google Scholar
• Canevari M, Castagliuolo I, Brun P, Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery. Int J Pharm 2009;368:171-7
   PubMed Web of Science ®Google Scholar
• Davaran S, Hanaee J, Khosravi A. Release of 5-amino salicylic acid from acrylic type polymeric prodrugs designed for colon-specific drug delivery. J Control Release 1999;58:279-87
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Garzon-Aburbeh A, Natalini B, Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid. J Med Chem 1993;36:4201-7
   PubMed Web of Science ®Google Scholar
• Jung Y, Kim HH, Kim H, Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Eur J Pharm Sci 2006;28:26-33
   PubMed Web of Science ®Google Scholar
• Kim H, Huh J, Jeon H, N,N'-Bis(5-aminosalicyl)-L-cystine is a potential colon-specific 5-aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis. J Pharm Sci 2009;98:159-68
   PubMed Web of Science ®Google Scholar
• Kim H, Jeon H, Kong H, A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon. Mol Pharmacol 2006;69:1405-12
   PubMed Web of Science ®Google Scholar
• Jung YJ, Lee JS, Kim HH, Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res 1998;21:179-86
   PubMed Web of Science ®Google Scholar
• Inoue M, Morikawa M, Tsuboi M, Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs. Jpn J Pharmacol 1979;29:9-16
   PubMedGoogle Scholar
• Larsen C, Harboe E, Johansen M, Macromolecular prodrugs. XVI. Colon-targeted delivery–comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal (GI) tract. Pharm Res 1989;6:995-9
   PubMed Web of Science ®Google Scholar
• Herzog R, Leuschner J. Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. Arzneimittelforschung 1995;45:300-3
   PubMed Web of Science ®Google Scholar
• Crotty B, Jewell DP. Drug therapy of ulcerative colitis. Br J Clin Pharmacol 1992;34:189-98
   PubMed Web of Science ®Google Scholar
• Friend DR, Chang GW. Drug glycosides: potential prodrugs for colon-specific drug delivery. J Med Chem 1985;28:51-7
   PubMed Web of Science ®Google Scholar
• Conchie J, Macdonald DC. Glycosidases in the mammalian alimentary tract. Nature 1959;184(Suppl 16):1233
   PubMed Web of Science ®Google Scholar
• Haeberlin B, Rubas W, Nolen HW III, In vitro evaluation of dexamethasone-beta-D-glucuronide for colon-specific drug delivery. Pharm Res 1993;10:1553-62
   PubMed Web of Science ®Google Scholar
• Cui N, Friend DR, Fedorak RN. A budesonide prodrug accelerates treatment of colitis in rats. Gut 1994;35:1439-46
   PubMed Web of Science ®Google Scholar
• Jung YJ, Doh MJ, Kim IH, Prednisolone 21-sulfate sodium: a colon-specific pro-drug of prednisolone. J Pharm Pharmacol 2003;55:1075-82
   PubMed Web of Science ®Google Scholar
• Kong H, Kim Y, Lee Y, Sulfate-conjugated methylprednisolone: evaluation as a colon-specific methylprednisolone prodrug and comparison with sulfate-conjugated prednisolone and dexamethasone. J Drug Target 2009;17:159-67
   PubMed Web of Science ®Google Scholar
• Kim I, Kong H, Lee Y, Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine. Pharm Res 2009;26:415-21
   PubMed Web of Science ®Google Scholar
• Kong H, Lee Y, Hong S, Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis. J Drug Target 2009;17:450-8
   PubMed Web of Science ®Google Scholar
• McLeod AD, Friend DR, Tozer TN. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. J Pharm Sci 1994;83:1284-8
   PubMed Web of Science ®Google Scholar
• McLeod AD, Fedorak RN, Friend DR, A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterology 1994;106:405-13
   PubMed Web of Science ®Google Scholar
• Yano H, Hirayama F, Arima H, Preparation of prednisolone-appended alpha-, beta- and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior. J Pharm Sci 2001;90:493-503
   PubMed Web of Science ®Google Scholar
• Yano H, Hirayama F, Kamada M, Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Release 2002;79:103-12
   PubMed Web of Science ®Google Scholar
• Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37
   PubMed Web of Science ®Google Scholar
• Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 1960;235:433-7
   PubMed Web of Science ®Google Scholar
• Ho DH, Townsend L, Luna MA, Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986;6:781-4
   PubMed Web of Science ®Google Scholar
• Lee J, Rho J, Yang Y, Synthesis and in vitro evaluation of N-nicotinoylglycyl-2-(5-fluorouracil-1-yl)- D,L-glycine as a colon-specific prodrug of 5-fluorouracil. J Drug Target 2007;15:199-205
   PubMed Web of Science ®Google Scholar
• Jung YJ, Kim HH, Kong HS, Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res 2003;26:264-9
   PubMed Web of Science ®Google Scholar
• Brondsted H, Kopecek J. Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm Res 1992;9:1540-5
   PubMed Web of Science ®Google Scholar
• Dubin P, Wright KL. Reduction of azo food dyes in cultures of Proteus vulgaris. Xenobiotica 1975;5:563-71
   PubMed Web of Science ®Google Scholar
• Shamat MA. The role of the gastrointestinal microflora in the metabolism of drugs. Int J Pharm 1993;97:1-13
   Web of Science ®Google Scholar
• Kim IH, Kong HS, Choi BI, Synthesis and in vitro properties of dexamethasone 21-sulfate sodium as a colon-specific prodrug of dexamethasone. Drug Dev Ind Pharm 2006;32:389-97
   PubMed Web of Science ®Google Scholar
• Basit AW, Newton JM, Lacey LF. Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm 2002; 237:23-33
   PubMed Web of Science ®Google Scholar
• Jung YJ, Lee JS, Kim YM. Colon-specific prodrugs of 5-aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J Pharm Sci 2001;90:1767-75
   PubMed Web of Science ®Google Scholar
• Zhou SY, Fleisher D, Pao LH, Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999;27:479-85
   PubMed Web of Science ®Google Scholar
• Christrup LL, Moss J, Steffansen B. Prodrugs. In: Swarbrick J, Boylan JC, editors, Encyclopedia of pharmaceutical technology. Volume 13. Marcel Dekker, Inc.; 1988. p. 39-70
   Google Scholar
• Stella VJ. Case for prodrugs. In: Stella VJ, Borchardt RT, Hageman MJ, , editors, Prodrugs: challenges and rewards. New York: Springer Science; 2007. p. 3-36
   Google Scholar
• Gao SQ, Lu ZR, Petri B, Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release 2006;110:323-31
   PubMed Web of Science ®Google Scholar
• Hiipakka RA, Zhang HZ, Dai W, Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 2002;63:1165-76
   PubMed Web of Science ®Google Scholar
• Ojima M, Satoh K, Gomibuchi T, The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone–in vivo and in vitro studies. Nippon Naibunpi Gakkai Zasshi 1990;66:584-96
   PubMedGoogle Scholar
• Yuan H, Ji WS, Wu KX, Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol 2006;12:4578-81
   PubMed Web of Science ®Google Scholar